OR WAIT null SECS
The expansion will include new suites for the development and clinical manufacturing of drug product intermediates and drug products and cGMP suites for early-phase cGMP manufacture.
Lonza announced on Nov. 30, 2020 that it is expanding its particle engineering and drug product capabilities at its Bend, OR site.
The expansion will include new suites for the development and clinical manufacturing of drug product intermediates and drug products using spray-drying, hot-melt extrusion, and melt-spray-congeal processing and cGMP suites for early-phase cGMP manufacturing featuring added storage, gowning, and a customer in-plant viewing corridor, a company press release said.
“We continue to see increased demand for development, clinical, and commercial manufacture of particle-engineered intermediates and finished drug products,” said Paul Granberry, managing director, Lonza Bend, in the press release. “Dedicated, fit-for-purpose suites, infrastructure, and systems are critical for supporting the needs of our customers’ early-phase programs.”
“Our customers look to Lonza to rapidly advance challenging molecules and meet increasingly difficult target product profiles,” added Christian Dowdeswell, vice president and global head of Commercial Development for Small Molecules business, Lonza, in the press release. “We listened, and this new investment is aimed directly at meeting those needs.”